ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,909.03
      -1.11%
      US Tech 100
      20,607.20
      0.00%
      Dow Jones
      42,528.36
      -0.42%
      Brent Oil
      77.585
      0.68%
      Bitcoin
      95,923.64
      -1.01%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. AMEX

      6. AEON Biopharma Inc (AEON) Quote

      AEON Biopharma Inc

      AEON Biopharma Inc (AEON)

      AMEX
      0.221
      0.00
      (0.00%)
      Closed January 08 4:00PM
      Delayed by 15 minutes
      0.00
      0.00
      (0.00%)
      After Hours: -
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      0.221
      Bid
      -
      Ask
      -
      Volume
      -
      0.00 Day's Range 0.00
      0.16 52 Week Range 17.17
      Market Cap
      8.834M
      Previous Close
      0.221
      Open
      -
      Last Trade
      Last Trade Time
      -
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      2,692,514
      Shares Outstanding
      39,970,693
      Dividend Yield
      -
      PE Ratio
      0.37
      Earnings Per Share (EPS)
      0.6
      Revenue
      52.75M
      Net Profit
      24.05M

      About AEON Biopharma Inc

      AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-... AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. It is also engaged in the Phase II clinical study of ABP-450 for the treatment of cervical dystonia. Cervical dystonia, also known as spasmodic torticollis, is a neurological condition. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Blank Checks
      Headquarters
      Wilmington, Delaware, USA
      Founded
      2022
      AEON Biopharma Inc is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker AEON. The last closing price for AEON Biopharma was $0.22. Over the last year, AEON Biopharma shares have traded in a share price range of $ 0.16 to $ 17.17.

      AEON Biopharma currently has 39,970,693 shares outstanding. The market capitalization of AEON Biopharma is $8.83 million. AEON Biopharma has a price to earnings ratio (PE ratio) of 0.37.

      Ask ADVFN Intelligence (AI)

      AEON Latest News

      More News

      FeaturedEzFill Holdings, Inc. Successfully Closes Acquisition of Shell Fleet, Accelerating Nationwide Mobile Fueling Expansion

      19 hours ago

      Form 424B5 - Prospectus [Rule 424(b)(5)]

      22 hours ago
      Edgar (US Regulatory)

      Form 8-K - Current report

      January 06 2025
      Edgar (US Regulatory)

      Form 424B5 - Prospectus [Rule 424(b)(5)]

      January 06 2025
      Edgar (US Regulatory)

      Form 8-K - Current report

      December 20 2024
      Edgar (US Regulatory)

      Form SC 13G - Statement of Beneficial Ownership by Certain Investors

      November 14 2024
      Edgar (US Regulatory)

      Form 424B3 - Prospectus [Rule 424(b)(3)]

      November 13 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 13 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      October 07 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      September 04 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.3064-58.09632157760.52740.590.16358742450.21419257CS
      4-0.402-64.52648475120.6230.90.1681626920.22562362CS
      12-0.789-78.11881188121.011.160.1626925140.24600237CS
      26-0.799-78.33333333331.023.740.1620773651.14863725CS
      52-6.999-96.93905817177.2217.170.1610927811.30046431CS
      156-9.919-97.820512820510.1417.170.167687321.4370652CS
      260-9.919-97.820512820510.1417.170.167687321.4370652CS

      AEON - Frequently Asked Questions (FAQ)

      What is the current AEON Biopharma share price?
      The current share price of AEON Biopharma is $ 0.221
      How many AEON Biopharma shares are in issue?
      AEON Biopharma has 39,970,693 shares in issue
      What is the market cap of AEON Biopharma?
      The market capitalisation of AEON Biopharma is USD 8.83M
      What is the 1 year trading range for AEON Biopharma share price?
      AEON Biopharma has traded in the range of $ 0.16 to $ 17.17 during the past year
      What is the PE ratio of AEON Biopharma?
      The price to earnings ratio of AEON Biopharma is 0.37
      What is the cash to sales ratio of AEON Biopharma?
      The cash to sales ratio of AEON Biopharma is 0.17
      What is the reporting currency for AEON Biopharma?
      AEON Biopharma reports financial results in USD
      What is the latest annual turnover for AEON Biopharma?
      The latest annual turnover of AEON Biopharma is USD 52.75M
      What is the latest annual profit for AEON Biopharma?
      The latest annual profit of AEON Biopharma is USD 24.05M
      What is the registered address of AEON Biopharma?
      The registered address for AEON Biopharma is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801
      Which industry sector does AEON Biopharma operate in?
      AEON Biopharma operates in the BLANK CHECKS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      AAPYKurv Yield Premium Strategy Apple AAPL ETF
      $ 26.50
      (0.00%)
      		0
      AAPXT Rex 2X Long Apple Daily Target ETF
      $ 30.07
      (0.00%)
      		0
      AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026
      $ 26.3952
      (0.00%)
      		0
      AAAUGoldman Sachs Physical Gold ETF Shares
      $ 26.195
      (0.00%)
      		0
      AAAAlternative Access First Priority CLO Bond ETF
      $ 25.1297
      (0.00%)
      		0
      AAPYKurv Yield Premium Strategy Apple AAPL ETF
      $ 26.50
      (0.00%)
      		0
      AAPXT Rex 2X Long Apple Daily Target ETF
      $ 30.07
      (0.00%)
      		0
      AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026
      $ 26.3952
      (0.00%)
      		0
      AAAUGoldman Sachs Physical Gold ETF Shares
      $ 26.195
      (0.00%)
      		0
      AAAAlternative Access First Priority CLO Bond ETF
      $ 25.1297
      (0.00%)
      		0
      AAPYKurv Yield Premium Strategy Apple AAPL ETF
      $ 26.50
      (0.00%)
      		0
      AAPXT Rex 2X Long Apple Daily Target ETF
      $ 30.07
      (0.00%)
      		0
      AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026
      $ 26.3952
      (0.00%)
      		0
      AAAUGoldman Sachs Physical Gold ETF Shares
      $ 26.195
      (0.00%)
      		0
      AAAAlternative Access First Priority CLO Bond ETF
      $ 25.1297
      (0.00%)
      		0

      AEON Discussion

      View Posts
      0210 0210 1 day ago
      93m shs traded = 50m buys + 8m(?) vs. 35m sells: https://ih.advfn.com/stock-market/AMEX/aeon-biopharma-AEON/trades
      👍️0
      0210 0210 1 day ago
      new lows still, hah! hmmm.....interesting AEON teens & twenties.
      👍️0
      0210 0210 2 days ago
      aeon aeON AEON https://www.benzinga.com/news/25/01/42821213/why-aeon-biopharma-stock-is-down-65-today
      👍️0
      0210 0210 2 days ago
      A/S 500m O/S 40m Float 10m. 70m traded so far today. buys > sells. hmmm....
      👍️0
      0210 0210 2 days ago
      AEON 19-20cents way below all-time VWAPs and 50cents $20m new offering price!? hmmm....chap 11 pps? lolol.
      👍️0
      ErnieBilco ErnieBilco 2 days ago
      Offering meltdown TIME TO BUY
      👍️0
      glenn1919 glenn1919 3 months ago
      AEON............................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 4 months ago
      AEON new 52=week low
      👍️0
      willlbone willlbone 5 months ago
      Dilution.
      👍️0
      glenn1919 glenn1919 6 months ago
      AEON.......................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 6 months ago
      AEON under $3
      👍️0
      glenn1919 glenn1919 6 months ago
      AEON..............................................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
      👍️0
      DewDiligence DewDiligence 6 months ago
      AEON repositions ABP-450 as_a potential Botox biosimilar:

      https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000126.html

      AEON is nearly insolvent (#msg-174417740), so it’s hard to see how they complete a phase-3 trial to obtain FDA approval using the 351(k) pathway.

      This looks like another instance of Zebra’s Law.

      Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.
      👍️0
      Monksdream Monksdream 6 months ago
      AEON new 52 week low
      👍️0
      Monksdream Monksdream 6 months ago
      AEON new 52 week low
      👍️0
      DewDiligence DewDiligence 7 months ago
      AEON—>55% workforce reduction—ABP-450 clinical development suspended:

      https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000294.html Upon securing additional capital, we would be positioned to announce a revised clinical development strategy for our pipeline of ABP-450 programs. AEON is all but insolvent—see #msg-174417740.

      Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.
      👍️0
      DewDiligence DewDiligence 8 months ago
      AEON has a liquidity problem—1Q24 results:

      https://www.globenewswire.com/news-release/2024/05/14/2881873/0/en/AEON-Biopharma-Reports-First-Quarter-2024-Financial-Results.html

      Net current assets at 3/31/24 were negative ($13.5M). Hence, even after accounting for the $15.0M AEON received from its supplier, Daewoong in an Apr 2024 private placement, net current assets as of today are either close to zero or negative.

      No CC.
      👍️0
      DewDiligence DewDiligence 8 months ago
      AEON plows on despite setbacks:

      https://www.globenewswire.com/news-release/2024/05/09/2878729/0/en/AEON-Biopharma-Provides-Update-on-Development-Pipeline.html
      👍️0
      Monksdream Monksdream 8 months ago
      AEON new 52+ week low
      👍️0
      DewDiligence DewDiligence 8 months ago
      AEON—(-53%)—reports failed phase-2 in migraine prevention:

      https://finance.yahoo.com/news/aeon-biopharma-announces-preliminary-top-110000987.html AEON Biopharma…today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint. This is AEON’s second phase-2 failure in migraine, having whiffed in a prior phase-2 for treatment (rather than prevention) of episodic migraine (#msg-173058579).

      AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau, sourced from Korea's Daewoong.

      AEON’s lead indication had previously been cervical dystonia, but AEON backed off from CD after RVNC reported stellar data in that indication.

      Please see #msg-172274907 for related info.
      👍️0
      DewDiligence DewDiligence 9 months ago
      Dilution from the redemption of warrants:

      https://www.sec.gov/ix?doc=/Archives/edgar/data/0001837607/000183760724000017/aeon-20240329x8k.htm
      👍️0
      trglaa trglaa 9 months ago
      What happened here today?
      👍️0
      DewDiligence DewDiligence 9 months ago
      AEON 4Q23 financials:

      https://www.globenewswire.com/news-release/2024/03/29/2854830/0/en/AEON-Biopharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
      👍️0
      DewDiligence DewDiligence 10 months ago
      AEON updates plans for migraine program:

      https://finance.yahoo.com/news/aeon-biopharma-announces-clinical-productive-203000664.html
      👍️0
      DewDiligence DewDiligence 10 months ago
      AEON sells $15M of convertible debt to_supplier, Daewoong:

      https://finance.yahoo.com/news/aeon-biopharma-announces-15-million-202900910.html
      👍️0
      DewDiligence DewDiligence 12 months ago
      AEON presents phase-2 data in cervical dystonia:

      https://finance.yahoo.com/news/aeon-biopharma-presents-positive-clinical-210500488.html

      CD had been AEON’s lead indication for ABP-450, but AEON changed gears and made episodic migraine the lead indication after RVNC reported Daxxify data in CD (https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm ). When AEON’s phase-2 in episodic migraine failed in Oct 2023 (#msg-173058579), CD again became the lead indication by default.

      The above PR also includes preclinical data for ABP-450 in PTSD (!?).

      AEON needs to raise a significant amount of cash to conduct a phase-3 trial in any indication (#msg-173211412).

      Reminder: ABP-450, sourced from Korea’s Daewoong, is the exact same toxin as EOLS’ Jeuveau. See #msg-172274907 for background info.
      👍️0
      DewDiligence DewDiligence 1 year ago
      AEON needs to raise cash very soon:

      https://www.globenewswire.com/news-release/2023/11/13/2779046/0/en/AEON-Biopharma-Reports-Third-Quarter-2023-Financial-Results.html The Company reported cash, cash equivalents and investments were approximately $16.2 million as of September 30, 2023.

      The Company believes its cash, cash equivalents and investments will be sufficient to fund its planned clinical studies, as well as support corporate operations into mid-December 2023. No quarterly CC.
      👍️0
      DewDiligence DewDiligence 1 year ago
      AEON phase-2 trial_in episodic migraine misses_ primary_endpoint:

      https://finance.yahoo.com/news/aeon-biopharma-announces-topline-results-200500504.html On the primary endpoint, the topline data showed ABP-450 had a treatment effect with mean reductions in MMD [monthly migraine days] of 4.8 days at the 150U dose (n = 99) and 5.0 days at the 195U dose (n = 108), compared to only 4.2 days in placebo (n = 98) at weeks 21-24, but did not meet statistical significance… Episodic migraine is (was) ABP-450’s lead indication. The lead indication had previously been cervical dystonia, but AEON backed off from CD due, presumably, to RVNC’s stellar dataset in that indication.

      AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau. Please see #msg-172274907 for related info.
      👍️0
      DewDiligence DewDiligence 1 year ago
      AEON's trading liquidity is so low it doesn't take much to move the share price. Today's news was actually minor in the overall scheme of things insofar as AEON has apparently put the brakes on its clinical program in cervical dystonia in order to pursue episodic migraine.
      👍️0
      trglaa trglaa 1 year ago
      Nice run today.
      👍️0
      DewDiligence DewDiligence 1 year ago
      AEON presents phase-2 data in cervical dystonia:

      https://finance.yahoo.com/news/aeon-biopharma-presents-positive-results-120000687.html

      Note: Episodic migraine, rather than cervical dystonia, is now AEON’s lead indication for ABP-450. This change is presumably due to RVNC’s robust data in cervical dystonia and the recent FDA approval of Daxxify for CD.

      See #msg-172274963 for related info.
      👍️0
      DewDiligence DewDiligence 1 year ago
      AEON's initial press release:

      https://finance.yahoo.com/news/aeon-biopharma-announces-closing-business-110000037.html
      👍️0
      TESLA777 TESLA777 1 year ago
      $AEON This is the one Im watching/trading tomorrow....GLTY......
      👍️0
      DewDiligence DewDiligence 1 year ago
      AEON’s corporate slide presentation:

      https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm

      Notably, AEON’s lead indication is now episodic migraine. AEON’s lead indication was previously cervical dystonia, so it seems reasonable to surmise that RVNC’s stellar data in CD altered AEON’s plans.
      👍️0
      DewDiligence DewDiligence 1 year ago
      AEON seeks_to_compete_in_the therapeutic—(rather than aesthetic)—market_for botulinum toxin. AEON's botulinum toxin, ABP-450 is the exact same product as EOLS’ Jeuveau, sourced from Korea's Daewoong.
      👍️0
      DewDiligence DewDiligence 1 year ago
      AEON Biopharma begins_trading_7/24/23_under_the_symbol, AEON, following the closing of the SPAC merger with PMGM:

      https://finance.yahoo.com/news/priveterra-acquisition-corp-announces-completion-202700149.html
      👍️0

      Your Recent History

      AMEX
      AEON
      AEON Biopharma
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads